MWNA
CMMB

Marshall Wace North America’s Chemomab Therapeutics CMMB Stock Holding History

Marshall Wace North America’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-11,009
Closed -$837K – 1466
2021
Q2 		$837K Buy
+11,009
New +$1.08M ﹤0.01% 1065

Other funds holding CMMB

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
YAVAPFMC
Yahav Achim Ve Achayot - Provident Funds Management Company Tel-Aviv, Israel $144M AUM 82.62% 1-Year Est. Return

Marshall Wace North America's CMMB Position: Q3 2021 in Review

Marshall Wace North America sold out of Chemomab Therapeutics (CMMB) in Q3 2021, closing a stake of 11,009 shares — an estimated $837K sold.

Marshall Wace North America first reported a position in CMMB in Q2 2021 and held it in 1 quarter. The position peaked at $837K in Q2 2021. 15 funds tracked by Wall St. Rank hold CMMB as of Q3 2021.

  • Marshall Wace North America reported no remaining Chemomab Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Marshall Wace North America sold 11,009 Chemomab Therapeutics shares in Q3 2021, an estimated $837K.
  • Marshall Wace North America first reported a position in Chemomab Therapeutics in Q2 2021 and held it in 1 quarter.
  • Marshall Wace North America's Chemomab Therapeutics position peaked at $837K in Q2 2021.
  • 15 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.